Jose Vidal

Jose Vidal serves as Chief Executive Officer at CytoImmune Therapeutics. CytoImmune Therapeutics operates in the biotechnology sector with approximately 28.0 employees. The company is headquartered in San Juan, San Juan.

Industry & Role Insights

• • MessageCEO tracks 381 executives in the biotechnology sector.
• • Our database includes 201,469 c suite-level executives.

Cloudflare DNS Outlook Microsoft Office 365 CloudFlare Hosting Google Font API reCAPTCHA WordPress.org Mobile Friendly

immunotherapy cell therapy nk cells car-nk cells cancer treatment solid tumors hematologic malignancies allogeneic therapies tumor-specific antigens natural killer cell expansion clinical trials regulatory affairs biologics gmp manufacturing cell manufacturing immune system modulation carcinogenic agents dual-targeted therapies cytokine secretion bla development car engineering therapeutic antibodies drug development clinical pharmacology cord blood nk cells fda compliance investigational drugs process development research collaborations biopharmaceuticals cancer immunotherapy cellular therapies drug efficacy advanced cancer treatments patient care solutions cancer vaccines tumor microenvironments biologics manufacturing chimeric antigen receptors immune response enhancement biotherapeutic development translational medicine clinical research regenerative medicine biomanufacturing oncology drug development manufacturing capacity cancer biomarkers biologics regulations health care health wellness & fitness hospital & health care

CB

Chip Baird Chief Executive Officer at 2seventy bio at 2seventy bio

JL

Jason Loveridge CEO at 4SC AG

MM

Marie Moores Chief Operating Officer at AB Cavalli Coach & Consultant

JR

Julie Rubinstein President and Chief Operating Officer at Adaptive Biotechnologies Corp.

CH

Chris Harano President and CEO at Advanced BioCatalytics

Outreach Guidance — biotechnology Sector

Technology executives make decisions on infrastructure, tooling, and partnerships. When reaching out to Jose Vidal, lead with your value proposition relative to the stack they currently use. Generic pitches perform poorly; specific technical relevance is key.

Jose Vidal's Position in the MessageCEO Database

• •Jose Vidal is 1 of 1 verified executive contact we track at CytoImmune Therapeutics.
• •365 verified executive contacts in biotechnology are in the MessageCEO database.
• •10 verified executive contacts in San Juan are in the database.
• •8 verified contacts work at biotechnology companies in the 28.0 employee range (same size as CytoImmune Therapeutics).

Executive contact data compiled from public business filings, LinkedIn public profiles, company press materials, and verified outbound email testing. We do not publish personal addresses or sensitive identifiers. Methodology & sources · Removal requests handled at /remove-info · Updated June 2026.

How do I reach Jose Vidal directly?

Jose Vidal's verified email address is available to MessageCEO Pro subscribers. They currently serve as Chief Executive Officer at CytoImmune Therapeutics. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does Jose Vidal work for?

Jose Vidal is Chief Executive Officer at CytoImmune Therapeutics, a company in the biotechnology sector with 28.0 employees. The company is based in San Juan, San Juan.

Can I pitch or sell to Jose Vidal?

As Chief Executive Officer at CytoImmune Therapeutics, Jose Vidal is a key decision-maker in the biotechnology sector. MessageCEO Pro gives you verified email to reach Jose Vidal directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is Jose Vidal in?

Jose Vidal works in the biotechnology industry as Chief Executive Officer at CytoImmune Therapeutics. MessageCEO provides verified contact information for executives across all major industries.

Is Jose Vidal's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. Jose Vidal's profile is kept up-to-date with the latest available information.

Last updated: June 26, 2026